Nevada-AACE Metabolic Bone Disease Day Program
Osteoporosis is a worldwide problem, affecting over 75 million people, and 10 million in the U.S alone. It is vital to keep physicians aware of the most current information regarding the identification, management and research that is involved with this disease. This involves a thorough understanding of bone biology, including the modeling and remodeling processes, as well as the accepted management of the conditions that result from the breakdown of bone.
Endocrinologists, endocrine NPs and PAs, nephrologists, rheumatologists, and primary care practitioners in Las Vegas, NV.
- Understand the basics of bone biology
- Review the key players involved in bone modeling and remodeling
- Discuss the consequences of disturbances in each pathway, and options for therapeutic intervention
- Review the principles underlying dual-energy x-ray absorptiometry (DXA)
- Understand how to interpret DXA scans and be familiar with common pitfalls in interpretation
- Incorporate DXA into diagnosing and managing patients with osteoporosis
- Identify patients that require a secondary causes work up for osteoporosis
- Discuss the evaluation of the patient with osteoporosis
- Discuss an approach to addressing abnormal results from a secondary causes work up
- Review AACE Guidelines on the selection of pharmacological agents for the management of osteoporosis
- Review current recommendations regarding duration of osteoporosis therapy
- Review current recommendations regarding combination therapy and sequential therapy
- Describe novel potential molecular targets for therapeutic intervention
- Identify new and emerging agents for treating osteoporosis
- Discuss new concepts in managing osteoporosis
- Identify rare skeletal diseases with new and emerging treatments
- Describe data supporting novel treatments for rare bone diseases
- Discuss new strategies for managing rare bone diseases
- Understand the distinction between CKD-MBD and Osteoporosis
- Understand how to make the diagnosis of osteoporosis in Stage 4-5 CKD
- Understand treatment pathways for both CKD-MBD and Osteoporosis at all stages of CKD
Bijan Ahrari, MD; E. Michael Lewiecki, MD, FACP, FACE; W. Reid Litchfield, MD, FACE, ECNU; Paul D. Miller, MD; Paul V. Tomasic, MD, MS, FACP, FACE; Nicholas Vernetti, MD, FACE
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the Nevada Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 4.25 AMA
- 4.25 Attendance